{"name":"Hikma Pharmaceuticals LLC","slug":"hikma-pharmaceuticals-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-01","label":"Onureg Phase 2 readout (Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma)","drug":"Onureg","drugSlug":"onureg","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-07-31","label":"Onureg Phase 2 readout (Myelodysplastic Syndromes)","drug":"Onureg","drugSlug":"onureg","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Carcemia","genericName":"Carcemia","slug":"carcemia","indication":"Other","status":"phase_2"},{"name":"Onureg","genericName":"Onureg","slug":"onureg","indication":"Other","status":"discontinued"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Biosimilar Infliximab","genericName":"Biosimilar Infliximab","slug":"biosimilar-infliximab","indication":"Rheumatoid arthritis","status":"marketed"}]}],"pipeline":[{"name":"Biosimilar Infliximab","genericName":"Biosimilar Infliximab","slug":"biosimilar-infliximab","phase":"marketed","mechanism":"Biosimilar infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Carcemia","genericName":"Carcemia","slug":"carcemia","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Onureg","genericName":"Onureg","slug":"onureg","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQTjc1ZUxSZ3BnZkUyd2JETmpQUm9WbDg5LVFReGdDTV9EbnhfQy1kenBJTWZTQUZjeVpENy1lSVZlVjBYU2loQzRTYkFXUnJDMm9aQVRoWUlnNklWMDFqRWN1WjBzMjA4S2V2blJJZEMwVlhsaDZVWFNEVHFHbHJkLWdOZnNySlhjY0l1Z3lRLWkzTjJtVm1RSHloc21MdXI4WXRIVmxfTmhBUWVZSVZOSGFYRmlvQWRxUkE?oc=5","date":"2026-03-24","type":"pipeline","source":"IPWatchdog.com","summary":"SCOTUS Grants Solicitor General Divided Argument in Hikma Induced Infringement Case - IPWatchdog.com","headline":"SCOTUS Grants Solicitor General Divided Argument in Hikma Induced Infringement Case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPeVFrb0JZRUJHN29WTTRVYjF3bTQyQ0pIMmZZZjdRdXdFa1NaaXY0VWlfaC1hQzR0TE1HdUtrMHNuZDNqZVZnYm1TMW5nemVWV0hoc1h5Q3ZPNHlXcDRBV3h3ZUQxSDZrUG84ckE3YU1vMGlqQnlWRDNaV1UtU19qWmkySVdOem1EZFpOZnZvTmxaNGRqbnI2dmhEVG9BMThXSjVmYy04c1pFRGRaWTgwSG5kUHdWXzMxZ2VrRlJudEVnTy1mZGlaUDRSM3dlVWY0VEE?oc=5","date":"2026-02-26","type":"pipeline","source":"reuters.com","summary":"Hikma Pharma's gloomy outlook kicks shares to more than three-year low - reuters.com","headline":"Hikma Pharma's gloomy outlook kicks shares to more than three-year low","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOMDZyV1E0ZHBpb2FQTy11ZG1Remc3bmlCMllfMExzN1l2UHZ0ZzEzVEJJamRwME5IdVhVeW8xZGViWXNBNkdOeEw1RGhwazVmbE00bDJrQ09BbzJyU3JobTBpcHVoTkFrRFJFdVU3ZE9Ubm8yZXhuMk5HOXg4MGFkUUE4a3h6cHM?oc=5","date":"2026-01-21","type":"regulatory","source":"JD Supra","summary":"Supreme Court Takes Up Hikma v. Amarin: Induced Infringement and Skinny Labels in the Crosshairs - JD Supra","headline":"Supreme Court Takes Up Hikma v. Amarin: Induced Infringement and Skinny Labels in the Crosshairs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPVWNpTkVsWFFLRVZaR21xZGNwLVpLZF9xUEZCanNudXYtTkI5QjBva3NUX2I1RUltM0R1Q1lBOVdUSHh3SW1mVnNDcVpMVkVHUG5DUDRuZGN5VVB6YnhlUDNVY0hpTGNZckpnNmJDU203UmlXWVVaRE43TmNGckZUSlp3cXRITVRUZkt4NUc1b1A1bjdRaS04V2JEUlN3YWpka01GRGlBbmdCaUxaWWdURGRkN2duQ2NX?oc=5","date":"2026-01-20","type":"regulatory","source":"Fierce Pharma","summary":"Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa - Fierce Pharma","headline":"Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPc1psbW9mb0QwN0lKRmVQRnRjUFNFSFFIRlZwT3hLMVdrT1NCdUtrbDVFOWZlUWE4OTN6czhaTktrSmhMWFJKSEpKd1B4THJTbV8zWDBpdGtJaDNnRlpEaFowU3NyMU5UZnBHUVFkRG1IUU8yRmlid3I1aXdVeF8wZGR1VE10b0RtSXF1Rl9idGRsQi1oenA5UEtFd3hrYkx2cWhFOUlSR1hxRGE2cW9oT3ZxaC1Wd2Y4NnEzeHNWdXVZdjU3c2Zja1dqZ1JDT3Y0SURTUWJwdjVPaGhXZTZqVTZOTU5TN0JVNjdLSVhpUTBqelJMWi1USVIybzdseWJLN1FrX0Izb2RiQ2dlalVVNV9JTDd1Z0V4SGJ0LWxHTjhkeGM0WTdLUW1n?oc=5","date":"2026-01-20","type":"regulatory","source":"VitalLaw.com","summary":"SUPREME COURT NEWS: Supreme Court agrees to review Hikma’s certiorari petition in ‘skinny label’ induced infringement dispute with Amarin - VitalLaw.com","headline":"SUPREME COURT NEWS: Supreme Court agrees to review Hikma’s certiorari petition in ‘skinny label’ induced infringement di","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQYkt6N0IxWVpsNkFBY0JwdWdlMlFrVlVXTkUzNkluT0Ztb2x3N0VXQ1pLSUZVRFhtZTF6TDFlY3FsUnJFbk5YblUtWFlWR25MV0hkS09rajRKdTA5czBJMjBPc1F3c3BZTG9yVkVaRTFXN0lwenFWY0RESTYtNHhfVWlzSnhuTjMwQXZLc2FLVUlhdTI3bElxSjE0aV8wSXJwUUxkZWhxSnc0TFVyTDBCSUFYLXpXazBMV2tJ?oc=5","date":"2025-11-06","type":"pipeline","source":"Proactive financial news","summary":"Hikma Pharma tumbles as injectables guidance cut - Proactive financial news","headline":"Hikma Pharma tumbles as injectables guidance cut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOcGJpSWVPeXJYMEx5bDhmNkRnRnlZUUIwUU5meGF4MjhZenNLYnZya29BVHFyYjhFWUNmaFRKNnk0WmxrS0ZvSWF6Y01SQnh2QXluQkNKWWpJWU5iLWlvZzN6Z3FsdWwyYTZ3OTdHaVBQSk91S2VEMjZKSkhBUjZVaGpYbS1KTGRUQkxn?oc=5","date":"2025-07-10","type":"trial","source":"Market Data Forecast","summary":"Middle East Pharmaceutical Market Size, Share & Growth, 2033 - Market Data Forecast","headline":"Middle East Pharmaceutical Market Size, Share & Growth, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPcFpkR241aTR1SnZoN09GcFhlb1pyQ05DMjRSaEtZOTQxRW9XZVVGdzJaaVFZd183M2RmUFpIajNLVEZEYW83c2pLcUgyMUpUOUxMSXVXdTdnZ01qQzVrT21pc18wZTRtRTRMOWkxUkZya1dJa1FGMW5FTmtTektmSGxyVUYzTHZORUFqQl9sM05VY3RiX0NjdmxJM3A5LUJ1S2t6REFXUG9NdDB5WEhuTnZXVnRockIyQnUwTVVR?oc=5","date":"2025-06-30","type":"pipeline","source":"Fierce Pharma","summary":"Hikma to splash $1B on US production and R&D, joining branded drugmakers' investment spree - Fierce Pharma","headline":"Hikma to splash $1B on US production and R&D, joining branded drugmakers' investment spree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOUmMzb3dCNU9lc1hDR3pmX2ttTnUtWEp1MWdkNjQ2NGd5WVlzaTdyekhpRlg4aDFMSHJkVHZlSW9wUTE2TmJoMDdPa19QczVySFM0MG5acTlqMV9XZ2k1V0p4U1BXYkFKc3hIWWotSWxrOEdjemN2cThIc09hWEQ2QTBkZnlzMnlRTk9hc1pBS0lVRndlN1RjU2Y2Sk9rdkloLWlJNDZ2NzVLX2Q3a3FMRjVwaUU2ZEFxOHllWmVB?oc=5","date":"2025-06-03","type":"pipeline","source":"The Columbus Dispatch","summary":"Ohio EPA fines Hikma Pharmaceuticals in Columbus $4,400 for violating hazardous waste laws - The Columbus Dispatch","headline":"Ohio EPA fines Hikma Pharmaceuticals in Columbus $4,400 for violating hazardous waste laws","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNV1k0VXFOQWgyNmY5b19FUmlhczZSU0FDalZtcjFyVk40MFY3N181Y2FpSWE4ZnZ4Q3ZTZ3lfVHBycE1vRk1Mbmx4d09RZHFnU3EzZktWbW1kRy1jdkcxRUxhYVVyaU1TaWFPVmowWEN3SE85UDY3WWFRZUxqZEpEQXozVXNkWWhXNG1zTS1CNVd1VGFraHFtR3VjRTFfVllsandEb0s2YlNSLUZpSUw5NTlveTJBTG1jbGc?oc=5","date":"2025-05-08","type":"pipeline","source":"reuters.com","summary":"Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case - reuters.com","headline":"Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxONm9uOWRxQ2RMV0dmVnJCSWh3QktIYk85WWE3aW9zQ1c1UmJ3ajhHQXN3VVE3UGk0RmtZT1psWkJreUo1eWcyUl9XUElQaUFuU3dxakRUMGxKZEpQQmNOVTVaVXl1eGpwd0xEbklEMExnZW5zelU1VHdqOVMzODFOTlNpWUhZS2IwMnNJMWFqN1VMTS1mbDBiMDVSRzJJdkpzeXFkRGx5dmdSOTNwTW10LTczTTZUaXkya3NsZW5YOExwZGFoNmpjXzd5TDJjVFhaRkVPVkJ2aUpfNGlMNnF1VQ?oc=5","date":"2025-04-10","type":"regulatory","source":"Crowell & Moring LLP","summary":"Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels” - Crowell & Moring LLP","headline":"Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels” - Crowell & Moring L","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5sZEdKQTFOZzVPdlR0bTNGTU5WWDIwdWtJRzV2QkZlVk1BYVpVY25QMThNMFRYTG40UU5KakNoQ19KLXNfQmpmd0c2bDBpZEl2VHdoRV9YdU9FMV9sQWpTWkhqeWF4NlA5XzBjamtmTjI2dm9EVmlMSktxaw?oc=5","date":"2024-06-25","type":"regulatory","source":"Patently-O","summary":"Amarin v. Hikma: Federal Circuit reverses Inducement Dismissal in Skinny-Label Case - Patently-O","headline":"Amarin v. Hikma: Federal Circuit reverses Inducement Dismissal in Skinny-Label Case - Patently","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_2":1,"discontinued":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}